FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Büchner

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Florian Nolte; Daniel Nowak; Verena Nowak; Mark Reinwald; Cristina Sauerland; Karsten Spiekermann; Thomas Büchner; Andreas Faldum; Benjamin Hanfstein; Anna Hecht; Wolf-Karsten Hofmann; Eva Lengfelder
In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival.
Anna Hecht; Wolf-Karsten Hofmann; Eva Lengfelder; Daniel Nowak; Verena Nowak; Cristina Sauerland; Karsten Spiekermann; Thomas Büchner; Andreas Faldum; Benjamin Hanfstein; Florian Nolte
High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia.
Till Schoofs; Isabell Schulze; Monika Stoll; Anika Witten; Christian Rohde; Frank Rosenbauer; Peter Schlenke; Shuchi Agrawal-Singh; Wolfgang E Berdel; Thomas Büchner; Nikolaj Dietrich; Martin Dugas; Stefanie Göllner; Klaus Hansen; Katja Hebestreit; Wolf-Karsten Hofmann; Hans-Ulrich Klein; Eva Lengfelder; Mads Lerdrup; Carsten Müller-Tidow
DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Büchner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Florian Nolte; Daniel Nowak; Verena Nowak; Mark Reinwald; Cristina Sauerland; Karsten Spiekermann; Thomas Büchner; Andreas Faldum; Benjamin Hanfstein; Anna Hecht; Wolf-Karsten Hofmann; Eva Lengfelder
In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival.
Leukemia research 2013;37(4):378-82.
2013: Anna Hecht; Wolf-Karsten Hofmann; Eva Lengfelder; Daniel Nowak; Verena Nowak; Cristina Sauerland; Karsten Spiekermann; Thomas Büchner; Andreas Faldum; Benjamin Hanfstein; Florian Nolte
High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia.
Annals of hematology 2013;92(4):443-9.
2013: Till Schoofs; Isabell Schulze; Monika Stoll; Anika Witten; Christian Rohde; Frank Rosenbauer; Peter Schlenke; Shuchi Agrawal-Singh; Wolfgang E Berdel; Thomas Büchner; Nikolaj Dietrich; Martin Dugas; Stefanie Göllner; Klaus Hansen; Katja Hebestreit; Wolf-Karsten Hofmann; Hans-Ulrich Klein; Eva Lengfelder; Mads Lerdrup; Carsten Müller-Tidow
DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding.
Blood 2013;121(1):178-87.
2013: Eva Lengfelder; Carsten Müller-Tidow; Cristina Sauerland; Stephanie Schneider; Susanne Schnittger; Beate Schultheis; Hubert Serve; Karsten Spiekermann; Bernhard Wörmann; Carlo Aul; Wolfgang E Berdel; Jan Braess; Thomas Büchner; Philipp Erben; Claudia Haferlach; Torsten Haferlach; Benjamin Hanfstein; Rüdiger Hehlmann; Achim Heinecke; Wolfgang Hiddemann; Wolf-Karsten Hofmann; Heinz A Horst; Karl-Anton Kreuzer; Utz Krug
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Annals of hematology 2013;92(1):41-52.
2012: Thomas Büchner; Hartmut Döhner; Konstanze Döhner; Gerhard Ehninger; Arnold Ganser; Joerg Hasford; Rüdiger Hehlmann; Gerhard Heil; Achim Heinecke; Wolfgang Hiddemann; Dieter Hoelzer; Verena S Hoffmann; Rainer Krahl; Michael Kramer; Jürgen Krauter; Utz Krug; Dietger W Niederwieser; Maria Cristina Sauerland; Markus Schaich; Richard F Schlenk; Sebastian Scholl; Daniela Späth; Wolfgang E Berdel; Markus Pfirrmann
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(29):3604-10.
2012: Klaus Metzeler; Vijay P S Rawat; Maria Cristina Sauerland; Richard F Schlenk; Karsten Spiekermann; Stefan K Bohlander; Jan Braess; Thomas Büchner; Lars Bullinger; Hartmut Döhner; Konstanze Döhner; Annika Dufour; Katrin E Edmaier; Michaela Feuring-Buske; Bernhard Heilmeier; Wolfgang Hiddemann; Christian Buske
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Blood 2012;120(10):2118-26.
2012: Philipp A Greif; Andreas Hauser; Tobias Herold; Wolfgang Hiddemann; Karl-Peter Hopfner; Eva Hoster; Purvi M Kakadia; Nikola P Konstandin; Stefan Krebs; Bianka Ksienzyk; Maria Cristina Sauerland; Friederike Schneider; Stephanie Schneider; Karsten Spiekermann; Martin Stanulla; Jutta Sturm; Belay Tizazu; Bernhard J Woermann; Marjan Yaghmaie; Evelyn Zellmeier; Tobias Benthaus; Wolfgang E Berdel; Helmut Blum; Jan Braess; Thomas Büchner; Petra Dörge; Annika Dufour; Alexander Graf; Stefan K Bohlander
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Blood 2012;120(2):395-403.
2012: Annika Dufour; Wolfgang Hiddemann; Eva Hoster; Purvi M Kakadia; Bianka Ksienzyk; Maria Cristina Sauerland; Friederike Schneider; Stephanie Schneider; Karsten Spiekermann; Marion Subklewe; Bernhard Wörmann; Tobias Benthaus; Wolfgang E Berdel; Stefan K Bohlander; Jan Braess; Thomas Büchner
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Annals of hematology 2012;91(7):1051-63.
2012: Rüdiger Liersch; Bob Löwenberg; Carsten Müller-Tidow; Christoph Schliemann; Christian Schwöppe; Iris Appelmann; Michael Bayer; Wolfgang E Berdel; Christoph Biermann; Thomas Büchner; Joachim Gerss; Wolfgang Hiddemann; Torsten Kessler; Rolf M Mesters
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.
Blood 2012;119(22):5215-20.
2012: Friederike Schneider; Stephanie Schneider; Michael Unterhalt; Bernhard J Wörmann; Evelyn Zellmeier; Tobias Benthaus; Wolfgang E Berdel; Stefan K Bohlander; Jan Braess; Thomas Büchner; Christian Buske; Annika Dufour; Michaela Feuring-Buske; Achim Heinecke; Wolfgang Hiddemann; Eva Hoster; Purvi M Kakadia; Gudrun Mellert; Maria Cristina Sauerland; Karsten Spiekermann
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.
Blood 2012;119(19):4383-6.
2012: Shuchi Agrawal-Singh; Nicole Bäumer; Anke Becker; Wolfgang E Berdel; Thomas Büchner; Martin Dugas; Gerhard Ehninger; Klaus Hansen; Antje Hascher; Fabienne Isken; Hans-Ulrich Klein; Gabriele Koehler; Steffen Koschmieder; Utz Krug; Michael McClelland; Peter Schlenke; Hubert Serve; Shailendra Vikram Singh; Christian Thiede; Nils Thoennissen; Yipeng Wang; Dae-Yeul Yu; Konstantin Agelopoulos; Carsten Müller-Tidow
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene.
Blood 2012;119(10):2346-57.
2012: Utz Krug; Wolfgang E Berdel; Christian Brandts; Thomas Büchner; Gesine Bug; Ulrich Dührsen; Gerhard Ehninger; Joachim Gerss; Anja Koschmieder; Steffen Koschmieder; Richard Noppeney; Christoph Röllig; Markus Schaich; Daniela Schwammbach; Hubert Serve; Björn Steffen; Matthias Stelljes; Christian Thiede; Nicola Tidow; Carsten Müller-Tidow
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
PloS one 2012;7(12):e52695.
2011: Utz Krug; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
The treatment of elderly patients with acute myeloid leukemia.
Deutsches Ärzteblatt international 2011;108(51-52):863-70.
2011: Matthias Stelljes; Renate Arnold; Dietrich W Beelen; Wolfgang E Berdel; Bjorna Berning; Jan Braess; Thomas Büchner; Achim Heinecke; Wolfgang Hiddemann; Ernst Holler; Joachim Kienast; Hans J Kolb; Carsten Müller-Tidow; Maria Cristina Sauerland; Rainer Schwerdtfeger; Hubert Serve; Gerda Silling; Karsten Spiekermann
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
Haematologica 2011;96(7):972-9.
2010: Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Lancet 2010;376(9757):2000-8.
2010: Claudia Hömme; Utz Krug; N Tidow; Bernd Schulte; Gabriele Kühler; Hubert Serve; Horst Bürger; Wolfgang E Berdel; Martin Dugas; Achim Heinecke; Thomas Büchner; Steffen Koschmieder; Carsten Müller-Tidow
Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.
Oncology reports 2010;24(1):47-56.
2010: Utz Krug; Michael Lübbert; Thomas Büchner
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Current opinion in hematology 2010;17(2):85-90.
2010: Annika Dufour; Friederike Schneider; Klaus Metzeler; Eva Hoster; Stephanie Schneider; Evelyn Zellmeier; Tobias Benthaus; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Jan Braess; Wolfgang Hiddemann; Stefan K Bohlander; Karsten Spiekermann
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):570-7.
2010: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo Coco; Tomoki Naoe; Dietger Niederwieser; Gert Ossenkoppele; MA Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Blood 2010;115(3):453-74.
2009: Eva Lengfelder; Claudia Haferlach; Susanne Saussele; Torsten Haferlach; Beate Schultheis; S Schnittger; Wolf-Dieter Ludwig; Peter Staib; Carlo Aul; A Grüneisen; W Kern; A Reichle; Hubert Serve; Wolfgang E Berdel; J Braess; K Spiekermann; Bernhard Wörmann; Maria Cristina Sauerland; Achim Heinecke; Wolfgang Hiddemann; Rüdiger Hehlmann; Thomas Büchner
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
Leukemia 2009;23(12):2248-58.
2009: Klaus Metzeler; Annika Dufour; Tobias Benthaus; Manuela Hummel; Maria Cristina Sauerland; Achim Heinecke; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Jan Braess; Karsten Spiekermann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5031-8.
2009: Jan Braess; Karsten Spiekermann; Peter Staib; Andreas Grüneisen; Bernhard Wörmann; Wolf-Dieter Ludwig; Hubert Serve; Albrecht Reichle; Rudolf Peceny; Daniel Oruzio; Christoph Schmid; Xaver Schiel; Marcus Hentrich; Christina Sauerland; Michael Unterhalt; Michael Fiegl; Wolfgang Kern; Christian Buske; Stefan Bohlander; Achim Heinecke; Herrad Baurmann; Dietrich W Beelen; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Blood 2009;113(17):3903-10.
2009: Thomas Büchner; Wolfgang E Berdel; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger; Carsten Müller-Tidow; Jan Braess; Karsten Spiekermann; Joachim Kienast; Peter Staib; Andreas Grüneisen; Wolfgang Kern; Albrecht Reichle; Georg Maschmeyer; Carlo Aul; Eva Lengfelder; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2008: Klaus Metzeler; Manuela Hummel; Clara D Bloomfield; Karsten Spiekermann; Jan Braess; Maria-Cristina Sauerland; Achim Heinecke; Michael Radmacher; Guido Marcucci; Susan P Whitman; Kati Maharry; Peter Paschka; Richard A Larson; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Wolfgang Hiddemann; Stefan K Bohlander; Christian Buske
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Blood 2008;112(10):4193-201.
2008: Thomas Büchner; Wolfgang E Berdel; Joachim Kienast
Cytogenetically normal acute myeloid leukemia.
The New England journal of medicine 2008;359(6):651; author reply 652-3.
2008: Dorle Messerer; Jutta Engel; Joerg Hasford; Markus Schaich; Gerhard Ehninger; Cristina Sauerland; Thomas Büchner; Andrea Schumacher; Rainer Krahl; Dietger Niederwieser; Jürgen Krauter; Arnold Ganser; Ursula Creutzig; Hartmut Döhner; Richard F Schlenk
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
Haematologica 2008;93(6):826-33.
2008: Torsten Kessler; M Mohr; Carsten Müller-Tidow; U Krug; U Brunnberg; B Mohr; Christoph Schliemann; Cristina Sauerland; Hubert Serve; Thomas Büchner; Wolfgang E Berdel; Rolf M Mesters
Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
Leukemia research 2008;32(3):491-4.
2008: Richard F Schlenk; Marcelo C Pasquini; Waleska S Pérez; Mei-Jie Zhang; Jürgen Krauter; Joseph H Antin; Asad Bashey; Brian J Bolwell; Thomas Büchner; Jean-Yves Cahn; Mitchell S Cairo; Edward A Copelan; Corey Cutler; Hartmut Döhner; Robert Peter Gale; Osman Ilhan; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Richard T Maziarz; Philip L McCarthy; Stephen D Nimer; Jorge Sierra; Martin S Tallman; Daniel J Weisdorf; Mary M Horowitz; Arnold Ganser
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(2):187-96.
2008: Ursula Creutzig; Thomas Büchner; Maria C Sauerland; Martin Zimmermann; Dirk Reinhardt; Hartmut Döhner; Richard F Schlenk
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Cancer 2008;112(3):562-71.
2007: Christoph Schliemann; Ralf Bieker; Nils Thoennissen; Joachim Gerss; Rüdiger Liersch; Torsten Kessler; Thomas Büchner; Wolfgang E Berdel; Rolf M Mesters
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia.
Leukemia 2007;21(9):1901-6.
2007: Thomas Büchner; Utz Krug; Wolfgang E Berdel; Achim Heinecke; Maria Cristina Sauerland; Bernhard Wörmann; Wolfgang Hiddemann
Maintenance for acute myeloid leukemia revisited.
Current treatment options in oncology 2007;8(4):296-304.
2007: Markus Schaich; Richard F Schlenk; Haifa-Kathrin Al-Ali; Hartmut Döhner; Arnold Ganser; Gerhard Heil; Thomas Illmer; Rainer Krahl; Jürgen Krauter; Cristina Sauerland; Thomas Büchner; Gerhard Ehninger
Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
Haematologica 2007;92(6):763-70.
2007: Shuchi Agrawal; Matthias Unterberg; Steffen Koschmieder; Udo zur Stadt; Uta Brunnberg; Walter Verbeek; Thomas Büchner; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Cancer research 2007;67(3):1370-7.
2007: Utz Krug; Hubert Serve; Carsten Müller-Tidow; Rolf M Mesters; Björn Steffen; Thomas Büchner; Wolfgang E Berdel
New molecular therapy targets in acute myeloid leukemia.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;176():243-62.
2006: Emma Kulimova; Elisabeth Oelmann; Guido Bisping; Joachim Kienast; Rolf M Mesters; Joachim Schwäble; Frank Hilberg; Gerald J Roth; Gerd Munzert; Martin Stefanic; Björn Steffen; Christian Brandts; Carsten Müller-Tidow; Astrid Kolkmeyer; Thomas Büchner; Hubert Serve; Wolfgang E Berdel
Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.
Molecular cancer therapeutics 2006;5(12):3105-12.
2006: Susanne Saussele; K Adam; Andreas Hochhaus; marie bene; Thomas Büchner; A Burnett; G Finazzi; Christa Fonatsch; E Gluckman; Nicola Gökbuget; David Grimwade; Torsten Haferlach; M Hallek; Joerg Hasford; Dieter Hoelzer; P Ljungman; Dietger Niederwieser; Hubert Serve; B Simonsson; T J de Witte; Rüdiger Hehlmann
[Clinical research at the European LeukemiaNet].
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
2006: Thomas Büchner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Joachim Kienast; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Eva Lengfelder; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Hartmut Eimermacher; Leopold Balleisen; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Susanne Saussele; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla; Rüdiger Hehlmann
[Clinical research within the German competence net "acute and chronic leukemias"].
Medizinische Klinik (Munich, Germany : 1983) 2006;101(5):414-20.
2006: Joëlle Tchinda; Sarah Volpert; Wolfgang E Berdel; Thomas Büchner; Jürgen Horst
Novel three-break rearrangement and cryptic translocations leading to colocalization of MYC and IGH signals in B-cell acute lymphoblastic leukemia.
Cancer genetics and cytogenetics 2006;165(2):180-4.
2006: Oliver Albrecht; Hubert Serve; Joëlle Tchinda; Michael Zühlsdorf; Thomas Büchner; Christoph Bremer; Reza Parwaresch; Wolfgang E Berdel
Acute myeloid leukemia presenting with a uterus tumor.
Annals of hematology 2006;85(1):58-9.
2005: Thomas Büchner; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Torsten Haferlach; Susanne Schnittger; Wolfgang Kern; Carlo Aul; Eva Lengfelder; Andrea Schumacher; Albrecht Reichle; Peter Staib; Leopold Balleisen; Hartmut Eimermacher; Andreas Grüneisen; Herbert Rasche; Maria Cristina Sauerland; Achim Heinecke; Rolf M Mesters; Hubert Serve; Joachim Kienast; Wolfgang Hiddemann
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Eva Lengfelder; Susanne Saussele; Andreas Weisser; Thomas Büchner; Rüdiger Hehlmann
Treatment concepts of acute promyelocytic leukemia.
Critical reviews in oncology/hematology 2005;56(2):261-74.
2005: Wolfgang Hiddemann; Karsten Spiekermann; Christian Buske; Michaela Feuring-Buske; Jan Braess; Torsten Haferlach; Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Wolfgang E Berdel; Bernhard Wörmann; Achim Heinecke; Cristina Sauerland; Thomas Büchner
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):235-45.
2005: Wolfgang E Berdel; Emma Kulimova; Astrid Kolkmeyer; Michael Zühlsdorf; Hubert Serve; Thomas Büchner; Elisabeth Oelmann
Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
Annals of hematology 2005;84(12):771-3.
2005: Mitrofanis Pavlidis; Tobias Stupp; Thomas Büchner; Heinrich Gerding
[Acute visual deterioration after "alternative therapy" in Russia].
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2005;102(9):902-5.
2005: Michael Fiegl; Thomas Büchner; Wolfgang Hiddemann; Jan Braess
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
Annals of hematology 2005;84(4):227-31.
2004: Rüdiger Hehlmann; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla
[The competence network "acute and chronic leukemias"].
Deutsche medizinische Wochenschrift (1946) 2004;129(49):2660-5.
2004: Richard F Schlenk; Axel Benner; Jürgen Krauter; Thomas Büchner; Cristina Sauerland; Gerhard Ehninger; Markus Schaich; B Mohr; Dietger Niederwieser; Rainer Krahl; Rita Pasold; Konstanze Döhner; Arnold Ganser; Hartmut Döhner; Gerhard Heil
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(18):3741-50.
2004: Joëlle Tchinda; Thomas E Neumann; Sarah Volpert; Wolfgang E Berdel; Thomas Büchner; Jürgen Horst
Characterization of chromosomal rearrangements in hematological diseases using spectral karyotyping.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2004;13(3):190-5.
2004: Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Dietger Niederwieser; Joerg Hasford
Cross-trial networking in AML: a step forward rather than corner cutting.
Leukemia research 2004;28(6):649-50.
2004: Torsten Haferlach; Wolfgang Kern; Claudia Schoch; Susanne Schnittger; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haematologica 2004;89(4):408-18.
2004: Rüdiger Hehlmann; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Dieter Hoelzer; Nicola Gökbuget; Karl Uberla
[Clinical research in the "acute and chronic leukemias"competence network ].
Der Internist 2004;45(4):384-92.
2004: Carsten Müller-Tidow; S K Metzelder; Horst Buerger; Jens Packeisen; Arnold Ganser; Gerhard Heil; K Kügler; G Adigüzel; Joachim Schwäble; Björn Steffen; Wolf-Dieter Ludwig; Achim Heinecke; Thomas Büchner; Wolfgang E Berdel; Hubert Serve
Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia.
Leukemia 2004;18(4):720-6.
2004: Carsten Müller-Tidow; Joachim Schwäble; Björn Steffen; Nicola Tidow; Burkhard Brandt; Kerstin Becker; Eric Schulze-Bahr; Hartmut Halfter; Ulf Vogt; Ralf Metzger; Paul M Schneider; Thomas Büchner; Christian Brandts; Wolfgang E Berdel; Hubert Serve
High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1241-9.
2004: Joachim Kienast; Matthias Stelljes; Bjorna Berning; Matthias Kröger; Maria Cristina Sauerland; Achim Heinecke; Claudia Schoch; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel
Transplantation strategies in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S136-7.
2004: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Carlo Aul; Eva Lengfelder; Rüdiger Hehlmann; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Hartmut Eimermacher; Norbert Frickhofen; Joachim Kienast; A Giagounidis; Maria Cristina Sauerland; Achim Heinecke
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Wolfgang Hiddemann; Wolfgang Kern; Achim Heinecke; Cristina Sauerland; Thomas Büchner
Priming with G-CSF in acute myeloid leukemia: preliminary data of the AMLCG.
Annals of hematology 2004;83 Suppl 1():S53-4.
2004: W Kern; Torsten Haferlach; Claudia Schoch; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Risk-adapted therapy of AML: the AMLCG experience.
Annals of hematology 2004;83 Suppl 1():S49-51.
2004: Joëlle Tchinda; Sarah Volpert; Rüdiger Liersch; Michael Zühlsdorf; Hubert Serve; T Neumann; Ingo Kennerknecht; Wolfgang E Berdel; Thomas Büchner; Jürgen Horst
A cryptic insertion (17;15) on both chromosomes 17 with lack of PML-RARA expression in a case of atypical acute promyelocytic leukemia.
Leukemia 2004;18(1):183-6.
2003: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Joëlle Tchinda; Sarah Volpert; Nicole McNeil; Thomas Neumann; Ingo Kennerknecht; Thomas Ried; Thomas Büchner; Hubert Serve; Wolfgang E Berdel; Jürgen Horst; Eva Hilgenfeld
Multicolor karyotyping in acute myeloid leukemia.
Leukemia & lymphoma 2003;44(11):1843-53.
2003: Thomas Büchner; Ulrike Schnorbus; Ulrike H Grenzebach; Tobias Stupp; Holger Busse
[Examination of preschool children for refractive errors. First experience using a handheld autorefractor].
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2003;100(11):971-8.
2003: Björn Steffen; Hubert Serve; Wolfgang E Berdel; Shuchi Agrawal; Bryan Linggi; Thomas Büchner; Scott W Hiebert; Carsten Müller-Tidow
Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(14):8448-53.
2003: Ralf Bieker; Christian Lerchenmüller; Jürgen Wehmeyer; Hubert Serve; Rolf M Mesters; Thomas Büchner; Wolfgang E Berdel
Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Oncology reports 2003;10(4):915-20.
2003: Ulrike H Grenzebach; Ulrike Schnorbus; Thomas Büchner; Holger Busse; Wolfgang Stoll
[Development of ocular motility following modified 3-wall decompression of the orbita in endocrine orbitopathy for functional and rehabilitative indication].
Klinische Monatsblätter für Augenheilkunde 2003;220(5):345-51.
2003: Andreas Reiter; Susanne Saussele; David Grimwade; Joseph L Wiemels; Mark Segal; Marina Lafage-Pochitaloff; Christoph Walz; Andreas Weisser; Andreas Hochhaus; Andreas Willer; Anja Reichert; Thomas Büchner; Eva Lengfelder; Rüdiger Hehlmann; Nicholas C P Cross
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.
Genes, chromosomes & cancer 2003;36(2):175-88.
2003: Torsten Haferlach; Claudia Schoch; Helmut Löffler; Winfried Gassmann; Wolfgang Kern; Susanne Schnittger; Christa Fonatsch; Wolf-Dieter Ludwig; Christian Wuchter; Brigitte Schlegelberger; Peter Staib; Albrecht Reichle; Uschi Kubica; Hartmut Eimermacher; Leopold Balleisen; Andreas Grüneisen; Detlef Haase; Carlo Aul; Jochen Karow; Eva Lengfelder; Bernhard Wörmann; Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2002: Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Joerg Hasford
Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies.
Leukemia research 2002;26(12):1073-5.
2002: Thomas Büchner; W Hiddemann
[Therapeutic strategies in acute myeloid leukemia].
Der Internist 2002;43(10):1203-4, 1207-11.
2002: Teresa Padró; Ralf Bieker; Sandra Ruiz; Martin B Steins; Stephan Retzlaff; H Bürger; Thomas Büchner; Torsten Kessler; F Herrera; Joachim Kienast; Carsten Müller-Tidow; Hubert Serve; Wolfgang E Berdel; Rolf M Mesters
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Leukemia 2002;16(7):1302-10.
2002: Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Thomas Büchner; Wolfgang Fegeler; Hannelore Bernhardt; N Brockmeyer; K-H Duswald; M Herrmann; D Heuser; U Jehn; Gudrun Just-Nübling; Meinolf Karthaus; Georg Maschmeyer; F-M Müller; J Müller; J Ritter; N Roos; Markus Ruhnke; A Schmalreck; R Schwarze; Günther Schwesinger; Gerda Silling
Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2002;21(5):337-52.
2002: Andrea Schumacher; Dieter Wewers; Achim Heinecke; Cristina Sauerland; Olaf M Koch; Jürgen van de Loo; Thomas Büchner; Wolfgang E Berdel
Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia.
Leukemia research 2002;26(4):355-62.
2002: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Helmut Löffler; Torsten Haferlach; Andrea Schumacher; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Herbert Rasche; Carlo Aul; Axel Heyll; Eva Lengfelder; Wolf-Dieter Ludwig; Georg Maschmeyer; Hartmut Eimermacher; Jochen Karow; Norbert Frickhofen; Wolf-Dietrich Hirschmann; Maria Cristina Sauerland
Acute myeloid leukemia: treatment over 60.
Reviews in clinical and experimental hematology 2002;6(1):46-59; discussion 86-7.
2002: Joëlle Tchinda; Sarah Volpert; Thomas Neumann; Ingo Kennerknecht; Jörg Ritter; Thomas Büchner; Wolfgang E Berdel; Jürgen Horst
Novel der(1)t(1;19) in two patients with myeloid neoplasias.
Cancer genetics and cytogenetics 2002;133(1):61-5.
2001: Christa Fonatsch; H Nowotny; E Pittermann-Höcker; Berthold Streubel; Ulrich Jäger; Peter Valent; Thomas Büchner; Klaus Lechner
Amplification of ribosomal RNA genes in acute myeloid leukemia.
Genes, chromosomes & cancer 2001;32(1):11-7.
2001: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Helmut Löffler; Claudia Schoch; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; R Andreesen; Leopold Balleisen; Detlef Haase; Hartmut Eimermacher; Carlo Aul; Herbert Rasche; J Uhlig; Andreas Grüneisen; H E Reis; J Hartlapp; Wolf-Dietrich Hirschmann; H J Weh; H J Pielken; Winfried Gassmann; Maria Cristina Sauerland; Achim Heinecke
Remission induction therapy: the more intensive the better?
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S41-4.
2001: Rolf M Mesters; Teresa Padró; Ralf Bieker; Martin B Steins; Michael Kreuter; M Göner; S Kelsey; Paul Scigalla; Walter Fiedler; Thomas Büchner; Wolfgang E Berdel
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
Blood 2001;98(1):241-3.
2001: Eva Hilgenfeld; Hesed Padilla-Nash; Nicole McNeil; Turid Knutsen; Cristina Montagna; Joëlle Tchinda; Jürgen Horst; W D Ludwig; Hubert Serve; Thomas Büchner; Wolfgang E Berdel; E Schröck; Thomas Ried
Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2.
British journal of haematology 2001;113(2):305-17.
2001: Christian Lerchenmüller; M Göner; Thomas Büchner; Wolfgang E Berdel
Rhinocerebral zygomycosis in a patient with acute lymphoblastic leukemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(3):415-9.
2001: G Jahns-Streubel; Jan Braess; Claudia Schoch; C Fonatsch; Detlef Haase; C Binder; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.
Leukemia 2001;15(3):377-84.
2001: Claudia Schoch; Torsten Haferlach; Detlef Haase; Christa Fonatsch; Helmut Löffler; Brigitte Schlegelberger; Peter Staib; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
British journal of haematology 2001;112(1):118-26.
2000: Masao Mizuki; R Fenski; Hartmut Halfter; Itaru Matsumura; R Schmidt; C Müller; W Grüning; K Kratz-Albers; S Serve; Claudia Steur; Thomas Büchner; Joachim Kienast; Yuzuru Kanakura; Wolfgang E Berdel; Hubert Serve
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Blood 2000;96(12):3907-14.
2000: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Wolf-Dieter Ludwig; Claudia Schoch; Torsten Haferlach; Georg Maschmeyer; Peter Staib; Carlo Aul; G A Heyll; Andreas Grüneisen; Herbert Rasche; J H Eimermacher; Leopold Balleisen; H J Pielken; H E Reis; Frank Griesinger; Albrecht Reichle; Maria Cristina Sauerland; Achim Heinecke
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
International journal of hematology 2000;72(3):285-9.
2000: Eva Lengfelder; Anja Reichert; Claudia Schoch; Detlef Haase; Torsten Haferlach; Helmut Löffler; Peter Staib; Axel Heyll; Wolfgang Seifarth; Susanne Saussele; Christa Fonatsch; Winfried Gassmann; Wolf-Dieter Ludwig; Andreas Hochhaus; D Beelen; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Rüdiger Hehlmann; Bernhard Wörmann; Wolfgang Hiddemann; Thomas Büchner
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia 2000;14(8):1362-70.
2000: Christian Wuchter; K Leonid; Velia Ruppert; Martin Schrappe; Thomas Büchner; Claudia Schoch; Torsten Haferlach; Jochen Harbott; Richard Ratei; Bernd Dörken; Wolf-Dieter Ludwig
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Haematologica 2000;85(7):711-21.
2000: Susanne Schnittger; U Kinkelin; Claudia Schoch; Achim Heinecke; Detlef Haase; Torsten Haferlach; Thomas Büchner; Bernhard Wörmann; Wolfgang Hiddemann; Frank Griesinger
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Leukemia 2000;14(5):796-804.
2000: Teresa Padró; Sandra Ruiz; Ralf Bieker; H Bürger; Martin B Steins; Joachim Kienast; Thomas Büchner; Wolfgang E Berdel; Rolf M Mesters
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
Blood 2000;95(8):2637-44.
2000: Berthold Streubel; Peter Valent; Ulrich Jäger; M Edelhäuser; Hannes Wandt; T Wagner; Thomas Büchner; Klaus Lechner; Christa Fonatsch
Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome.
Genes, chromosomes & cancer 2000;27(4):380-6.
1999: Christian Wuchter; Leonid Karawajew; Velia Ruppert; Thomas Büchner; Claudia Schoch; Torsten Haferlach; Richard Ratei; Bernd Dörken; Wolf-Dieter Ludwig
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Leukemia 1999;13(12):1943-53.
1999: Wolfgang Hiddemann; W Kern; Claudia Schoch; C Fonatsch; A Heinecke; Bernhard Wörmann; Thomas Büchner
Management of acute myeloid leukemia in elderly patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3569-76.
1999: W Kern; Claudia Schoch; C Fonatsch; A Heinecke; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
[The therapy of acute myeloid leukemia in patients of advanced age].
Deutsche medizinische Wochenschrift (1946) 1999;124(34-35):1005-14.
1999: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Winfried Gassmann; Torsten Haferlach; Christa Fonatsch; Detlef Haase; Claudia Schoch; Dieter K Hossfeld; Eva Lengfelder; Carlo Aul; Axel Heyll; Georg Maschmeyer; Wolf-Dieter Ludwig; Maria Cristina Sauerland; Achim Heinecke
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Blood 1999;93(12):4116-24.
1999: Frank Griesinger; M Pirò-Noack; N Kaib; M Falk; A Renziehausen; C Troff; D Grove; Susanne Schnittger; Thomas Büchner; J Ritter; Wolfgang Hiddemann; Bernhard Wörmann
Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome.
British journal of haematology 1999;105(1):241-55.
1999: Thomas Büchner
[Acute myeloid leukemia (AML)].
Praxis 1999;88(10):421-30.
1999: Nicola Gökbuget; Renate Arnold; Thomas Büchner; M Freund; Winfried Gassmann; Gerhard Heil; Wolfgang Hiddemann; Helmut Löffler; Thomas Lipp; Wolf-Dieter Ludwig; Georg Maschmeyer; Eckhard Thiel; D Messerer; Dieter Hoelzer
[Treatment of adult acute lymphoblastic leukemia].
Praxis 1999;88(10):407-20.
1999: Gerda Silling; Wolfgang Fegeler; N Roos; M Essink; Thomas Büchner
Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine.
Mycoses 1999;42 Suppl 2():101-4.
1999: Walter Verbeek; Bernhard Wörmann; P Koch; Carlo Aul; H F Hinrichs; Leopold Balleisen; J M Rowe; J Bennett; Detlef Haase; Christa Fonatsch; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
Journal of cancer research and clinical oncology 1999;125(6):369-74.
1998: K Kratz-Albers; M Zühlsdorp; Regine Leo; W L Berdel; Thomas Büchner; Hubert Serve
Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2.
Blood 1998;92(11):4485-7.
1998: Wolfgang Kern; Jan Braess; A Grote-Metke; H Kuse; R Fuchs; Dieter K Hossfeld; Albrecht Reichle; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group.
Leukemia 1998;12(10):1522-6.
1998: Wolfgang Kern; Carlo Aul; Georg Maschmeyer; R Kuse; A Kerkhoff; A Grote-Metke; Hartmut Eimermacher; Uschi Kubica; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.
Annals of hematology 1998;77(3):115-22.
1998: Wolfgang Kern; G Behre; T Rudolf; A Kerkhoff; A Grote-Metke; Hartmut Eimermacher; Uschi Kubica; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Cancer 1998;83(2):291-301.
1998: Wolfgang Kern; Carlo Aul; Georg Maschmeyer; R Schönrock-Nabulsi; Wolf-Dieter Ludwig; A Bartholomäus; P Bettelheim; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Leukemia 1998;12(7):1049-55.
1998: Martin Dreyling; K Schrader; Christa Fonatsch; Brigitte Schlegelberger; Detlef Haase; Claudia Schoch; W Ludwig; Helmut Löffler; Thomas Büchner; Bernhard Wörmann; Wolfgang Hiddemann; Stefan K Bohlander
MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.
Blood 1998;91(12):4662-7.
1998: Thomas Büchner; Holger Busse; Heinrich Gerding
[Intraocular lens implantation in childhood. Functional results and complications].
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 1998;95(5):307-16.
1998: Andrea Schumacher; Torsten Kessler; Thomas Büchner; Dieter Wewers; Jürgen van de Loo
Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy -- a longitudinal study.
Leukemia 1998;12(4):586-92.
1998: Berthold Streubel; Cristina Sauerland; Gerhard Heil; M Freund; H Bartels; Eva Lengfelder; Hannes Wandt; W D Ludwig; H Nowotny; M Baldus; B Grothaus-Pinke; Thomas Büchner; Christa Fonatsch
Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12.
British journal of haematology 1998;100(3):521-33.
1997: Claudia Schoch; Detlef Haase; Christa Fonatsch; Torsten Haferlach; Helmut Löffler; Brigitte Schlegelberger; Dieter K Hossfeld; R Becher; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
British journal of haematology 1997;99(3):605-11.
1997: Michael Zühlsdorf; M von Eiff; Michael Thomas; Thomas Büchner
Decrease in arterial oxygen partial pressure within the first 24 h of rhGM-CSF administration in AML patients.
European journal of haematology 1997;59(5):293-8.
1997: G Jahns-Streubel; C Reuter; U Auf der Landwehr; Michael Unterhalt; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Blood 1997;90(5):1968-76.
1997: Walter Verbeek; Bernhard Wörmann; P Koch; Carlo Aul; H Hinrichs; Leopold Balleisen; J M Rowe; J Bennett; Thomas Büchner; Wolfgang Hiddemann
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.
Annals of hematology 1997;74(5):205-8.
1997: C Reuter; Eberhard Schleyer; C Rolf; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Leukemia 1997;11(4):561-71.
1997: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Michael Zühlsdorf; R Rottmann; G Innig; G Maschmeier; Wolf-Dieter Ludwig; Maria Cristina Sauerland; Achim Heinecke
Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects.
Seminars in oncology 1997;24(1):124-31.
1997: Thomas Büchner
Treatment of adult acute leukemia.
Current opinion in oncology 1997;9(1):18-25.
1997: Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Cancer 1997;79(1):59-68.
1996: A Schumacher; T Kessler; A Riedel; Thomas Büchner; Jürgen van de Loo
[Quality of life and coping with illness in patients with acute myeloid leukemia].
Psychotherapie, Psychosomatik, medizinische Psychologie 1996;46(11):385-90.
1996: Torsten Haferlach; J M Bennett; Helmut Löffler; Winfried Gassmann; J W Andersen; NUKHET TUZUNER; P A Casslleth; Christa Fonatsch; Claudia Schoch; Brigitte Schlegelberger; R Becher; Eckhard Thiel; Wolf-Dieter Ludwig; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.
Leukemia & lymphoma 1996;23(3-4):227-34.
1996: Dieter Hoelzer; Nicola Gökbuget; R Arnold; Thomas Büchner; Mathias Freund; Winfried Gassmann; Gerhard Heil; Wolfgang Hiddemann; Helmut Löffler; T Lipp; Wolf-Dieter Ludwig; Georg Maschmeyer; Eckhard Thiel; D Messerer
[Acute lymphatic leukemia of the adult. Diagnosis, risk groups and therapy].
Der Internist 1996;37(10):994-1007.
1996: Claudia Schoch; Detlef Haase; Torsten Haferlach; Mathias Freund; H Link; Eva Lengfelder; Helmut Löffler; Thomas Büchner; Christa Fonatsch
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.
British journal of haematology 1996;94(3):493-500.
1996: C Müller; Joachim Kremerskothen; Michael Zühlsdorf; Uwe Cassens; Thomas Büchner; Angelika Barnekow; Olaf M Koch
Rapid quantitative analysis of protein tyrosine residue phosphorylation in defined cell populations in whole blood and bone marrow aspirates.
British journal of haematology 1996;94(3):461-3.
1996: Wolfgang Hiddemann; Eberhard Schleyer; Michael Unterhalt; Wolfgang Kern; Thomas Büchner
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Therapeutic drug monitoring 1996;18(4):341-9.
1996: Claudia Schoch; Detlef Haase; Torsten Haferlach; H Gudat; Thomas Büchner; Mathias Freund; H Link; Eva Lengfelder; Hannes Wandt; Maria Cristina Sauerland; Helmut Löffler; Christa Fonatsch
Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
Leukemia 1996;10(8):1288-95.
1996: B Gahn; Detlef Haase; Michael Unterhalt; M Drescher; Claudia Schoch; Christa Fonatsch; L W Terstappen; Wolfgang Hiddemann; Thomas Büchner; J M Bennett; Bernhard Wörmann
De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.
Leukemia 1996;10(6):946-51.
1996: Thomas Büchner; Achim Heinecke
The role of prognostic factors in acute myeloid leukemia.
Leukemia 1996;10 Suppl 1():S28-9.
1996: Dieter Hoelzer; Wolf-Dieter Ludwig; Eckhard Thiel; Winfried Gassmann; Helmut Löffler; Christa Fonatsch; Harald Rieder; Gerhard Heil; Barbara Heinze; R Arnold; Dieter K Hossfeld; Thomas Büchner; P Koch; Mathias Freund; Wolfgang Hiddemann; Georg Maschmeyer; Axel Heyll; Carlo Aul; T Faak; R Kuse; T H Ittel; M Gramatzki; Helmut Diedrich; K Kolbe; H G Fuhr; K Fischer; C Schadeck-Gressel; A Weiss; I Strohscheer; Bernd Metzner; U Fabry; Nicola Gökbuget; B Völkers; D Messerer; K Uberla
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Blood 1996;87(2):495-508.
1995: G Jahns-Streubel; C Reuter; Michael Unterhalt; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Leukemia 1995;9(11):1857-63.
1995: C Sperling; Thomas Büchner; U Creutzig; J Ritter; Jochen Harbott; Christa Fonatsch; C Sauerland; M Mielcarek; G Maschmeyer; Helmut Löffler
Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML.
Leukemia & lymphoma 1995;17(5-6):417-26.
1995: M von Eiff; Michael Zühlsdorf; Nikolaus Roos; Michael Thomas; Thomas Büchner; Jürgen van de Loo
Pulmonary infiltrates in patients with haematologic malignancies: clinical usefulness of non-invasive bronchoscopic procedures.
European journal of haematology 1995;54(3):157-62.
1994: Bernhard Wörmann; C Reuter; Michael Zühlsdorf; Thomas Büchner; Wolfgang Hiddemann
Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
Seminars in oncology 1994;21(6 Suppl 16):39-43.
1994: Wolfgang Hiddemann; Bernhard Wörmann; C Reuter; Eberhard Schleyer; Michael Zühlsdorf; A Böckmann; Thomas Büchner
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Seminars in oncology 1994;21(6 Suppl 16):33-8.
1994: Thomas Büchner
Hematopoietic growth factors in cancer treatment.
Stem cells (Dayton, Ohio) 1994;12(3):241-52.
1994: C Reuter; U Auf der Landwehr; Eberhard Schleyer; Michael Zühlsdorf; C Ameling; C Rolf; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Leukemia 1994;8(2):217-25.
1994: Thomas Büchner
The role of hematopoietic growth factors in the treatment of cancer and leukemias.
Acta haematologica Polonica 1994;25(2 Suppl 1):71-83.
1993: C Sperling; Thomas Büchner; C Sauerland; Christa Fonatsch; Eckhard Thiel; Wolf-Dieter Ludwig
CD34 expression in de novo acute myeloid leukaemia.
British journal of haematology 1993;85(3):635-7.
1993: Dieter Hoelzer; Eckhard Thiel; Wolf-Dieter Ludwig; Helmut Löffler; Thomas Büchner; Mathias Freund; Gerhard Heil; Wolfgang Hiddemann; Georg Maschmeyer; B Völkers
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
Leukemia 1993;7 Suppl 2():S130-4.
1993: C R Kusnierz-Glaz; D Normann; R Weinberg; R Fuchs; M Flasshove; Wolfgang Hiddemann; Jürgen van de Loo; Thomas Büchner
Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia.
Hematological oncology 1993;11(2):73-80.
1993: C Sperling; H Seibt-Jung; W Gassmann; B Komischke; C Sauerland; W Hiddemann; Helmut Löffler; Thomas Büchner; Eckhard Thiel; Wolf-Dieter Ludwig
Immunophenotype of acute myeloid leukemia: correlation with morphological characteristics and therapy response.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():381-92.
1993: Bernhard Wörmann; M Safford; S Könemann; Thomas Büchner; Wolfgang Hiddemann; L W Terstappen
Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():185-96.
1993: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; R Rottmann; Georg Maschmeyer; Wolf-Dieter Ludwig; Michael Zühlsdorf; K Buntkirchen; A Sander; J Aswald
The role of GM-CSF in the treatment of acute myeloid leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():21-4.
1992: Wolfgang Hiddemann; Eberhard Schleyer; Michael Unterhalt; Michael Zühlsdorf; C Rolf; C Reuter; U Kewer; C Uhrmeister; Bernhard Wörmann; Thomas Büchner
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Leukemia 1992;6(12):1273-80.
1992: Thomas Büchner; Wolfgang Hiddemann; U W Schaefer; Helmut Löffler; Georg Maschmeyer; Wolf-Dieter Ludwig; Carlo Aul; Bernd Lathan; Achim Heinecke
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.
Leukemia 1992;6 Suppl 4():68-70.
1992: L W Terstappen; M Safford; Michael Unterhalt; S Könemann; K Zurlutter; K Piechotka; M Drescher; C Aul; Thomas Büchner; Wolfgang Hiddemann
Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.
Leukemia 1992;6(10):993-1000.
1992: Thomas Büchner; Nikolaus Roos
Antifungal treatment strategy in leukemia patients.
Annals of hematology 1992;65(4):153-61.
1992: Wolfgang Hiddemann; Michael Kiehl; Michael Zühlsdorf; C Busemann; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Seminars in oncology 1992;19(2 Suppl 4):31-7.
1992: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Georg Maschmeyer; Dieter K Hossfeld; Wolf-Dieter Ludwig; M Nowrousian; Carlo Aul; U W Schaefer
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Leukemia 1992;6 Suppl 2():68-71.
1992: Dieter Hoelzer; Eckhard Thiel; Wolf-Dieter Ludwig; Helmut Löffler; Thomas Büchner; Mathias Freund; Gerhard Heil; Wolfgang Hiddemann; Georg Maschmeyer; B Völkers
The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group.
Leukemia 1992;6 Suppl 2():175-7.
1992: L W Terstappen; M Safford; S Könemann; M R Loken; K Zurlutter; Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann
Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Leukemia 1992;6(1):70-80.
1991: Thomas Büchner; Wolfgang Hiddemann; Monika Koenigsmann; Michael Zühlsdorf; Bernhard Wörmann; A Boeckmann; E A Freire; G Innig; Georg Maschmeyer; Wolf-Dieter Ludwig
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Blood 1991;78(5):1190-7.
1991: Wolfgang Hiddemann; M E Essink; Wolfgang Fegeler; Michael Zühlsdorf; C Sauerland; Thomas Büchner
Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia.
Cancer 1991;68(1):9-14.
1991: Mary M Horowitz; D Messerer; Dieter Hoelzer; Robert Peter Gale; A Neiss; K Atkinson; A J Barrett; Thomas Büchner; Mathias Freund; Gerhard Heil
Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission.
Annals of internal medicine 1991;115(1):13-8.
1991: Thomas Büchner; Wolfgang Hiddemann; G Löffler; Winfried Gassmann; Georg Maschmeyer; W Heit; Dieter K Hossfeld; H Weh; Wolf-Dieter Ludwig; Eckhard Thiel
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Seminars in hematology 1991;28(3 Suppl 4):76-9.
1991: Wolfgang Hiddemann; R Rottmann; Bernhard Wörmann; A Thiel; M Essink; C Ottensmeier; Mathias Freund; Thomas Büchner; Jürgen van de Loo
Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
Annals of hematology 1991;63(1):1-4.
1991: L W Terstappen; S Könemann; M Safford; M R Loken; K Zurlutter; Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann
Flow cytometric characterization of acute myeloid leukemia. Part 1. Significance of light scattering properties.
Leukemia 1991;5(4):315-21.
1991: Monika Koenigsmann; Wolfgang Hiddemann; Thomas Büchner
Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML.
Leukemia research 1991;15(1):37-41.
1990: Wolfgang Hiddemann; Thomas Büchner; Gerhard Heil; K Schumacher; Helmut Diedrich; Georg Maschmeyer; Anthony Ho; M Planker; S Gerith-Stolzenburg; R Donhuijsen-Ant
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Leukemia 1990;4(9):637-40.
1990: Wolfgang Hiddemann; Eberhard Schleyer; C Uhrmeister; Carlo Aul; Georg Maschmeyer; Achim Heinecke; Thomas Büchner
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Cancer treatment reviews 1990;17(2-3):279-85.
1990: M von Eiff; M Essink; Nikolaus Roos; Wolfgang Hiddemann; Thomas Büchner; Jürgen van de Loo
Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies.
Blut 1990;60(4):242-8.
1990: Wolfgang Hiddemann; W R Martin; C M Sauerland; Achim Heinecke; Thomas Büchner
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
Leukemia 1990;4(3):184-8.
1990: Wolfgang Hiddemann; Thomas Büchner
Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.
Blut 1990;60(3):163-71.
1990: M E Essink; Wolfgang Hiddemann; M von Eiff; Thomas Büchner; Jürgen van de Loo
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Haematology and blood transfusion 1990;33():558-9.
1990: M von Eiff; M Essink; Nikolaus Roos; H Schmidt; Wolfgang Hiddemann; Thomas Büchner; Jürgen van de Loo
Hepatosplenic candidiasis in acute leukemias.
Haematology and blood transfusion 1990;33():555-7.
1990: C Kusnierz-Glaz; M Reiser; B Hagemeister; Thomas Büchner; Wolfgang Hiddemann; Jürgen van de Loo
Magnetic resonance imaging follow-up in patients with acute leukemia during induction chemotherapy.
Haematology and blood transfusion 1990;33():351-6.
1990: C Krehmeier; Michael Zühlsdorf; Thomas Büchner; Wolfgang Hiddemann
Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM.
Haematology and blood transfusion 1990;33():129-32.
1990: Wolfgang Hiddemann; Michael Zühlsdorf; Bernhard Wörmann; Monika Koenigsmann; Thomas Büchner
Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial.
Leukemia research 1990;14(4):347-52.
1990: Thomas Büchner; Wolfgang Hiddemann; Monika Koenigsmann; M Zuehlsdorf; B Woermann; A Boeckmann; E Aguion Freire; G Innig; Georg Maschmeyer; Wolf-Dieter Ludwig
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapse.
Haematology and blood transfusion 1990;33():724-31.
1990: Wolf-Dieter Ludwig; Eckhard Thiel; Claus R Bartram; B R Kranz; A Raghavachar; Helmut Löffler; Arnold Ganser; Thomas Büchner; W Hiddemann; G Heil
Clinical importance of T-ALL subclassification according to thymic or prethymic maturation stage.
Haematology and blood transfusion 1990;33():419-27.
1990: Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner
Sequential decision strategy of the AML Cooperative Group studies.
Haematology and blood transfusion 1990;33():290-4.
1990: Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner
Predictive models for achievement of complete remission and duration of first remission in adult acute myeloid leukemia.
Haematology and blood transfusion 1990;33():285-9.
1990: Thomas Büchner; Wolfgang Hiddemann; S Blasius; P Koch; Georg Maschmeyer; C Tirier; H Sodomann; Rolf Kuse; Eckhard Thiel; Wolf-Dieter Ludwig
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Haematology and blood transfusion 1990;33():261-6.
1990: Thomas Büchner; Wolfgang Hiddemann; Georg Maschmeyer; W Ludwig; Helmut Löffler; M Nowrousian; Carlo Aul; Achim Heinecke
How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):97-9.
1990: Wolfgang Hiddemann; Bernhard Wörmann; D Messerer; R Springefeld; Thomas Büchner
Analysis of the cellular DNA and RNA content in acute leukemias by flow cytometry.
Journal of cancer research and clinical oncology 1990;116(5):507-12.
1989: Wolfgang Hiddemann; D Urbanitz; Peter Preusser; Wolf Achterrath; Thomas Büchner
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
Hematological oncology 1989;7(4):267-73.
1989: Eckhard Thiel; B R Kranz; A Raghavachar; Claus R Bartram; Helmut Löffler; D Messerer; Arnold Ganser; Wolf-Dieter Ludwig; Thomas Büchner; D Hoelzer
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia.
Blood 1989;73(5):1247-58.
1989: W Siegert; W Hiddemann; R Koppensteiner; Thomas Büchner; M Essink; Dieter Huhn; M Jung; L Marosi; T Martin; E Minar
Accidental overdose of mitoxantrone in three patients.
Medical oncology and tumor pharmacotherapy 1989;6(4):275-8.
1988: Thomas Büchner; Wolfgang Hiddemann; Michael Zühlsdorf; Monika Koenigsmann; A Böckmann; Jürgen van de Loo; G Schulz
Human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) treatment of patients with acute leukemias in aplasia and at high risk of early death.
Behring Institute Mitteilungen 1988;(83):309-12.
1988: M von Eiff; M Essink; Wolfgang Fegeler; S Schellong; H Schmidt; Wolfgang Hiddemann; Thomas Büchner; Jürgen van de Loo
[Clinical course and risk factors in patients with generalized mycoses].
Schweizerische medizinische Wochenschrift 1988;118(16):584-91.
1988: Dieter Hoelzer; Eckhard Thiel; Helmut Löffler; Thomas Büchner; Arnold Ganser; Gerhard Heil; E Kurrle; H Heimpel; P Koch; T Lipp
[Intensive combined therapy for high-risk ALL patients].
Onkologie 1988;11(1):18-24.
1988: Wolfgang Hiddemann; Thomas Büchner; M Essink; O Koch; W Stenzinger; Jürgen van de Loo
High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Onkologie 1988;11(1):10-2.
1988: D Hoelzer; E Thiel; H Löffler; Thomas Büchner; Arnold Ganser; Gerhard Heil; P Koch; M Freund; Helmut Diedrich; H Rühl
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.
Blood 1988;71(1):123-31.
1987: Dieter Hoelzer; Eckhard Thiel; Helmut Löffler; Thomas Büchner; Arnold Ganser; Gerhard Heil; E Kurrle; H Heimpel; P Koch; T Lipp
Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia.
Seminars in oncology 1987;14(2 Suppl 1):92-7.
1987: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; R Mertelsmann; M Planker; R Donhuijsen-Ant; E Lengfelder; Z Arlin; Thomas Büchner
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Seminars in oncology 1987;14(2 Suppl 1):73-7.
1987: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; R Mertelsmann; R Donhuijsen-Ant; E Lengfelder; Z Arlin; Thomas Büchner
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Blood 1987;69(3):744-9.
1987: Thomas Büchner; D Urbanitz; Wolfgang Hiddemann; P Koch; H J Pielken; R Kuse; A Mohr; Georg Maschmeyer; H Kreutzmann; F Wendt
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies].
Onkologie 1987;10(1):14-6.
1987: Wolfgang Hiddemann; H Kreutzmann; R Donhuijsen-Ant; M Planker; F C Wendt; Thomas Büchner
High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia.
Onkologie 1987;10(1):11-2.
1987: D Urbanitz; Thomas Büchner; H Pielken; P Koch; Wolf-Dieter Ludwig; G Maschmeier; Achim Heinecke; J van de Loo
Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
Haematology and blood transfusion 1987;30():64-8.
1987: Thomas Büchner; Wolfgang Hiddemann; D Urbanitz; H Kreutzmann; Georg Maschmeyer; F Wendt; R Kuse; A Mohr; W Gassmann; Helmut Löffler
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Haematology and blood transfusion 1987;30():57-63.
1987: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; H J Fuhr; R Donhuijsen-Ant; E Lengfelder; Thomas Büchner
Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.
Haematology and blood transfusion 1987;30():336-8.
1987: Helmut Löffler; W Kayser; Norbert Schmitz; Eckhard Thiel; D Hoelzer; Thomas Büchner; D Urbanitz; K Spiegel; D Messerer; Achim Heinecke
Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany.
Haematology and blood transfusion 1987;30():21-7.
1986: Wolfgang Hiddemann; H Kreutzmann; K Straif; Wolf-Dieter Ludwig; R Donhuijsen-Ant; E Lengfelder; Z Arlin; Thomas Büchner
High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study.
Onkologie 1986;9(3):144-6.
1986: Thomas Büchner; D Urbanitz; Wolfgang Hiddemann; P Koch; H J Pielken; R Kuse; A Mohr; Georg Maschmeyer; H Kreutzmann; F Wendt
[Acute myeloid leukemia (AML) in adults. Further development of therapy based on clinical phase II and phase III studies].
Onkologie 1986;9(2):83-91.
1985: Thomas Büchner; D Urbanitz; Wolfgang Hiddemann; H Rühl; Wolf-Dieter Ludwig; J Fischer; H C Aul; H A Vaupel; R Kuse; G Zeile
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(12):1583-9.
1985: Wolfgang Hiddemann; H Kreutzmann; Wolf-Dieter Ludwig; H C Aul; R Donhuijsen-Ant; E Lengfelder; Thomas Büchner
Mitozantrone and high-dose cytarabine in refractory adult acute myeloid leukaemia.
Lancet 1985;2(8453):508-9.
1985: W Hiddemann; Wolf Achterrath; D Urbanitz; Peter Preusser; Leopold Balleisen; Thomas Büchner
[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
Onkologie 1985;8(3):181-4.
1985: D Urbanitz; H J Pielken; P Koch; Thomas Büchner; Wolfgang Hiddemann; Achim Heinecke; F Wendt; G Maschmeier; J van de Loo
Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Onkologie 1985;8(3):157-9.
1985: Thomas Büchner; D Urbanitz; H Rühl; J Fischer; R Kuse
Role of chemotherapy for AML in remission.
Lancet 1985;1(8439):1224-5.
1985: Dieter Hoelzer; Eckhard Thiel; Helmut Löffler; H Bodenstein; Thomas Büchner; R Engelhardt; Arnold Ganser; D Messerer; H Rühl; T Zwingers
Risk groups in a multicenter pilot study for treatment of acute lymphoblastic and acute undifferentiated leukemia in adults.
Haematology and blood transfusion 1985;29():48-50.
1984: W Hiddemann; Wolf Achterrath; D Urbanitz; Peter Preusser; Leopold Balleisen; B Kirchhof; W Stenzinger; Thomas Büchner
[Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Onkologie 1984;7(4):214-6.
1984: Thomas Büchner; D Urbanitz; B Emmerich; J Fischer; A Heinecke; Wolfgang Hiddemann; M Pfreundschuh; H Rühl; F Wendt
Long-term remission in acute myelogenous leukaemia.
Lancet 1984;1(8376):571.
1983: Dieter Hoelzer; Eckhard Thiel; Helmut Löffler; H Bodenstein; Thomas Büchner; D Messerer
Multicentre pilot study for therapy of acute lymphoblastic and acute undifferentiated leukemia in adults.
Haematology and blood transfusion 1983;28():36-40.
1982: Thomas Büchner; D Urbanitz; B Emmerich; J Th Fischer; H H Fülle; Achim Heinecke; Dieter K Hossfeld; K M Koeppen; L Labedzki; Helmut Löffler; M R Nowrousian; M Pfreundschuh; Hans Pralle; H Rühl; F C Wendt
Multicentre study on intensified remission induction therapy for acute myeloid leukemia.
Leukemia research 1982;6(6):827-31.